Association of C-type lectin-like receptor 2 and galectin-1 with portal vein system thrombosis in HBV-related liver cirrhosis.

BACKGROUND AND AIMS

Hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis. Portal venous system thrombosis (PVST) is a major complication of liver cirrhosis. Recently, it has been shown that C-type lectin-like receptor 2 (CLEC-2) and galectin-1 participate in the activation and aggregation of platelets, thereby promoting the development of thrombosis. This cross-sectional study aims to evaluate the association of serum CLEC-2 and galectin-1 levels with PVST in patients with HBV-related liver cirrhosis.

METHODS

Overall, 65 patients with HBV-related liver cirrhosis were included, of whom 23 had PVST and 42 did not have. Serum CLEC-2 and galectin-1 levels were measured using enzyme-linked immunosorbent assay kits. PVST was assessed by contrast-enhanced computed tomography and/or magnetic resonance imaging scans. Subgroup analyses were conducted according to the degree and location of PVST.

RESULTS

Patients with PVST had significantly higher serum CLEC-2 ( = 0.006) and galectin-1 ( = 0.009) levels than those without. Patients with partial/complete PVST or fibrotic cord ( = 0.007; = 0.002), but not those with mural PVST ( = 0.199; = 0.797), had significantly higher serum CLEC-2 and galectin-1 levels than those without PVST. Patients with superior mesenteric vein thrombosis had significantly higher serum CLEC-2 ( = 0.013) and galectin-1 ( = 0.025) levels than those without PVST. Patients with main portal vein thrombosis had higher serum CLEC-2 ( = 0.020) and galectin-1 ( = 0.066) levels than those without PVST, but the difference in serum galectin-1 level was not significant between them.

CONCLUSION

Serum CLEC-2 and galectin-1 levels may be associated with the presence of PVST in HBV-related cirrhotic patients, but this association should be dependent upon the degree of PVST.